請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29048
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙 | |
dc.contributor.author | Chih-Chieh Tseng | en |
dc.contributor.author | 曾智傑 | zh_TW |
dc.date.accessioned | 2021-06-13T00:36:56Z | - |
dc.date.available | 2007-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-25 | |
dc.identifier.citation | ◎ Branscum AJ, Gardner IA, Johnson WO. Estimation of diagnostic-test sensitivity and specificity through Bayesian modeling. Prev Vet Med. 2005;68:145-163.
◎ Chang AR, Liang XM, Chan A, Chan M, Teo RM, Johnson PJ. The use of brush cytology and directed biopsies for the detection of nasopharyngeal carcinoma and precursor lesions. Head Neck 2001; 23:637-645. ◎ Chen HH, Duffy SW, Tabar L. A markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positivie predictive value for mammography in breast cancer screening. The Statistician 1996;45:307-317. ◎ Chen HH, Yen MF, Wu HM, Chiu YS, Chen LS. Perspective of breast cancer screening in Asian: An era of multiple detection modalities. 2005 International Asian Conference for Cancer Screening. ◎ Chen MR, Liu MY, Hsu SM, Fong CC, Chen CJ, Chen IH, Hsu MM, Yang CS, Chen JY. Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma biopsy as a screening test for NPC patients. J Med virol 2001;64:51-57. ◎ Cheng WM, Chan KH, Chen HL, Luo RX, NG S, Luk W, Zheng BJ et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002;97:489-492. ◎ Day NE et al. Estimation the sensitivity of a screen test. J Epidemiol commun Heal. 1985;39:364-366. ◎ Dendukuri N, Joseph L. Bayesian approaches to modeling the conditional dependence between multiple diagnostic tests. Biometrics 2001;57:158-167. ◎ Eddy DM. Screening for cancer: Theory, analysis and design.1980. ◎ Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley M. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004;112:1036-1041. ◎ Feng P, Chan SH, Soo MY, Liu D, Guan M, Ren EC, Hu H. Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma. Cancer 2001;92:1872-80. ◎ Ho HC, Ng MN, Kwan HC, Chau JC. Epstein-barr virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976;34:655-659. ◎ Hao SP, Tsang NM, Chang KP. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer. 2003;97:1909-13. ◎ Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg 2004;131:651-654. ◎ Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol 1995;141:263-72. ◎ Kerekhanjanarong V, Sitawarin S, Sakdikul S, Saengpanich S, Chindavijak S, Supiyaphun P, Voravud N, Mutirangura A. Telomerase assay and nested polymerase chain reaction from nasopharyngeal swabs for early noninvasive detection of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2000;123:624-629. ◎ Krishna SM, James S, Kattoor J, Balaram P. Serum EBV DNA as a biomarker in primary nasopharyngeal carcinoma of Indian origin. Jpn J Clin Oncol 2004;34:307-311. ◎ Leung SF, Tam JS, Chan A, Zee B, Chan L, Huang DP, Hasselt AV, Johnson PJ, Lo D. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr Virus DNA and anti-Epstein_Barr viral capsid antigen IgA antibody. Clin Chemistry 2004;50:339-345. ◎ Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT, Hao SP, Chen IH, Hong JH. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001;23:194-200. ◎ Liu MY, Chang YL, Ma J, Yang HL, Hsu MM, Chen CJ, Chen JY, Yang CS. Evaluation of multiple antibodies to Epstein-Barr Virus as markers for detecting patients with nasopharyngeal carcinoma. J Med Virol 1997;52:262-269. ◎ Lo YM, Chan YS, Lo KW, Leung SF, Chan JZ, Lee CK, Hjelm NM et al. Ouantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191. ◎ Low WK, Leong JL, Goh YH, Fong KW. Diagnostic value of Epstein-Barr serology in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2000;123:505-507. ◎ Mo H, Deng M, Hong M, al e. Value of biopsy with nasopharyngeal fibroscopy in patients infected by EB virus without typically clinical symptom. Cancer(Chinese) 2000;19:69-71. ◎ Ng WT, Yau TK, Yung R, Sze WM, Tsang A, Law A, Lee A. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998-1001. ◎ Pakin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. 2002.Vol VIII. International Agency for Research on Cancer: Lyon. ◎ Pearson GR, Weiland LH, Nell HB, Taylor W, Earle J, Mulroney SE, Goepfert H et al. Application of Epstein-Barr virus serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983;51:260-268. ◎ Sham JS, Wei W, Zong YS, Choy D, Guo YQ, Yan L, Lin ZX, Ng MH. Detection of subclinical nasopharyngeal carcinoma by fiberoptic endoscopy and multiple biopsy. Lancet 1990;335:371-374. ◎ Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX. Comparison of plasma Epstein-Barr virus DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004;100:1162-1170. ◎ Sheen TS, Ko JY, Chang YL, Chang YS, Huang YT, Chang Y, Tsai CH, Hsu MM. Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck 1998;20:732-738. ◎ Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000;6:1046-1051. ◎ Spiegelhalter D, Best NG, Carlin BP, Line AD. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B 2002;64:583-640. ◎ Spiegelhalter D, Thomas A, Best N, Gilks W.2005. BUGS: Bayesian Inference Using Gibbs Sampling, Version 14. MRC Biostatistics Unit, Cambridge. http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml. ◎ Stevens S, Verkuijlen S, Hariwiyanto B, Harijadi, Paramita DK, Fchiroh Jajah, Adham Marlinda, Tan IB et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 2006;119:608-614. ◎ Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803-821. ◎ Tong J, Tsang R, Lo KW, Woo J, Kwong J, Chan M, Chang A, Hasselt C, Huang D, To KF. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal brushing samples from patients with NP carcinoma. Clin Cancer Res 2002;8:2612-2619. ◎ Tsang R, Vlantis A, Ho R, Tam J, To KF, Hasselt AV. Sensitivity and specificity of Epstein-Barr virus IgA tilter in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004;26:598-602. ◎ Tune CE, Liavaag PG, Freeman JL, Brekel M, Shpitzer T, Kerrebijn J, Payne D et al. Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 1999;91:796-800. ◎ Wei W, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2043-2054. ◎ Yang X, Goldstein AM, Chen CJ, Rabkin CS, Chen JY, Cheng YJ, Hsu WL et al. Distribution of Epstien-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 2006;118:780-784. ◎ Zeng Y, Liu Y, Liu C, Chen S, Wei J, Zhu J, Zai H. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Inter Virol. 1980;13:162-168. ◎ Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. Prospectives studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985;36:545-547. ◎ Zong YS, Sham J, Ou XT, Guo YQ, Zheng SA, Liang JS, Qiu H. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992;69:3-7. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29048 | - |
dc.description.abstract | 從篩檢實務面來看,利用單一檢測工具篩檢疾病時雖然有方法簡便和價格便宜的優點,但是卻有敏感度和精確度不足的問題。為了增加篩檢敏感度和精確度,我們就需要合併多重檢測工具的方式,然而多重檢測工具之使用在方法學上我們會遇到一些問題,是單一檢測工具無法解決的問題,例如多重檢測工具合併後的敏感度和精確度、檢測工具多早前可以偵測出疾病,以及如何應用多重篩檢工具敏感度及精確度於多重檢測工具的成本效益問題。以鼻咽癌而言,利用單一工具EBV VCA IgA篩檢鼻咽癌時,會有精確度不足及偽陽性太高的問題。為了同時增加篩檢工具的敏感度和精確度,就需要合併多重鼻咽癌的檢測工具。然而合併了多重檢測工具後,篩檢的成本也隨之提高,因此就需要各種篩檢方法經濟效益的分析。本論文主要研究的目的為:(1)利用貝氏固定和隨機模式進行單一檢測工具敏感度和精確度的整合分析模式。(2)多重檢測工具的條件相依模式。(3)利用多階段模式估計多重檢測工具的臨床偵測前期與敏感度之關係。(4)利用(3)的結果進行鼻咽癌的多重檢測工具的成本效益分析。
本研究以發展多重篩檢工具的方法學並將之應用於鼻咽癌早期發現,其架構如下: 1. 以系統性文獻回顧方式,搜尋Medline和PubMed兩大外文資料庫,計收錄關鍵字含screening, Ebstein-barr virus (EBV)和Nasopharyngeal carcinoma文章計36篇,由於各研究間存在著異質性,因此我們分別以貝氏固定效應模式和貝氏隨機效應模式進行整合性分析,得到鼻咽癌篩檢單一工具的敏感度及精確度。 2. 進一步進行同時考慮兩種工具的整合性分析,由於兩種測量工具存在生物相似性,因此我們引入貝氏條件相依模式進行整合性分析。 3. 利用敏感度和臨床偵測前期之間的關係求算利用不同檢測工具進行篩檢時,由該工具最早可偵測時間點到臨床症狀發生之時間間隔。 4. 考慮利用兩種工具進行檢測時,族群內的個體可能存在何種工具較早可偵測到的順序不一致的情況,因此我們發展一混合性多階段疾病自然史模式,利用電腦模擬方式產生虛設世代,並進行參數估計及模式驗證。 5. 利用(4)的結果進行僅用單一工具(EBV VCA IgA或Nasopharyngoscope)及併用兩種工具相較於不篩檢時的經濟評估。 本研究貝氏隨機效應模式整合分析的結果發現敏感度最高的是EBV BamHI-W[中位數為91% (95%CI=67-97%)],其次為EBV VCA IgA (cross-sectional)、Nasopharyngeal swab、EBV VCA IgA、EBV EA IgA、Nasopharyngoscope及EBV EBNA。精確度最高的是Nasopharyngoscope [中位數為98% (95%CI=66-99%)],其次為EBV EA IgA、EBV VCA IgA (cross-sectional)、EBV BamHI-W、EBV EBNA、Nasopharyngeal swab及EBV VCA IgA。貝氏固定效應模式亦有相似的發現,但由模式的DIC值顯示大部份隨機模式均較固定模式來的好,除了鼻咽拭子之外。再利用多重檢測工具的敏感度、轉移速率和臨床偵測前期的關連,可得利用EBV BamHI-W檢測的臨床症前期約為2.79年,鼻咽拭子約為2.77年,EBV VCA IgA約為2.68年,EBV EA IgA、EBV EBNA及鼻咽鏡為2.34年,鼻咽細胞學為2.22年,合併鼻咽內視鏡和EBV VCA IgA、合併EBV EA IgA和EBV VCA IgA及合併EBV EBNA和EBV VCA IgA為2.97年。合併EBV BamHI-W和EBV VCA IgA 3.01年。 利用混合性多階段疾病自然史模式所得估計結果接近提供的真值,利用估計值得到僅使用EBV VCA IgA、僅使用鼻咽內視鏡及合併兩種工具的敏感度分別為87.6%, 72.4%及97.4%,與之前整合式分析結果相近。進一步利用以上參數比較未篩檢,利用EBV VCA IgA及鼻咽鏡每一年或每兩年篩檢一次,結果發現和未篩檢比較,每2年EBV VCA IgA篩檢的增加成本效益比例(ICER)是NT365,095、每年EBV VCA IgA篩檢的增加成本效益比例(ICER)是NT442,145,而每年合併EBV VCA IgA和鼻咽鏡篩檢的增加成本效益比例(ICER)是NT1,091,533。和未篩檢比較,每2年EBV VCA IgA篩檢17,857人可以減少一個鼻咽癌死亡。每年EBV VCA IgA篩檢23,622人可以減少一個鼻咽癌死亡。每年合併EBV VCA IgA和鼻咽鏡篩檢21,739人可以減少一個鼻咽癌死亡。 本研究最大新穎想法是將多階段模式疾病隨時間進展之概念與篩檢敏感度之相關進行聯結及互轉,此方法若應用於篩檢實務,將可提供做篩檢政策之參考,如篩檢間隔的決定及成本效益分析。 | zh_TW |
dc.description.abstract | Disease screening with single detection modality is convenient and cheap, but it may be less effectiveness in terms of sensitivity and specificity. In order to solve this problem, multiple detection modalities may be needed. However, the methodology of combining multiple detection modalities is difficult, such as the combined sensitivity and specificity, detection ability, and cost-effectiveness analysis. Take screening of nasopharyngeal carcinoma (NPC) with EBV VCA IgA for example. The specificity of EBV VCA IgA is not good enough that the false positive rate is too high. Although multiple detection modalities can raise sensitivity and specificity at the same time, it will also increase the cost of screening. Therefore, the cost-effectiveness analysis of multiple detection modalities ensures. The purpose of this study is to complete (1) the meta-analysis of sensitivity and specificity of each detection modality using Bayesian fixed-effect and random-effect model, (2) conditional dependency model of multiple detection modalities, (3) the relation between sensitivity and sojourn time using multi-state model, (4) the cost-effectiveness of multiple detection modalities for NPC.
The methodology part of multiple detection modalities is described as following: (1) We systemically searched Medline and PubMed with the key words of screening, Ebstein-barr virus(EBV) and nasopharyngeal carcinoma. The meta-analysis of the included 36 literature was performed with Bayesian fixed-effect and random-effect model to deal with the heterogeneity between each study. The results of sensitivity and specificity of each detection modality were obtained. (2) We used Bayesian conditional dependency model to estimate the combined sensitivity and specificity of detection modalities. This model adjusted with the biological correlation between combined detection modalities. (3)With the relation of sensitivity and pre-clinical detectable phase (PCPD, sojourn time), we estimated the earliness of detectable phase of each modalities. (4)We proposed a multi-state model for a mixture type of tumor progression. We also simulated the parameters for the mixture type model with the method of Monte Carlo simulation. Validation of the parameters was also performed. (5) We completed the cost-effectiveness analysis of NPC screening with different screening strategies using the parameters we generated in (4). The results of meta-analysis of the sensitivity for different detection modalities for nasopharyngeal carcinoma with Bayesian random-effect model are described as following. Serology of EBV BamHI-W region gene is the most sensitive detection modality (median value of 91%), followed by nasopharyngeal swab , EBV VCA IgA , EBV EA IgA , EBV EBNA, and nasopharyngoscope. In the same way, the most specific detection modality is nasopharyngoscope (median value of 98%), followed by EBV EA IgA, nasopharyngeal swab, EBV BamHI-W, EBV VCA IgA and EBV EBNA. The results of Bayesian fixed-effect model were similar to that of random-effect model. Using DIC (Deviation information criteria) to compare the two models, we found the random-effect model is better than fixed-effect model. The results of PCDP of each detection modalities were obtained with the relation between sensitivities, transitional rates, and PCDP. The PCDP of EBV BamHI-W is 2.79 year, nasopharyngeal swab is 2.77 year, EBV VCA IgA is 2.68 year, EBV EA IgA, EBV EBNA and nasopharyngoscope are 2.34 year, and nasopharyngeal cytology is 2.22 year. The PCDP of combining nasopharyngoscope and EBV VCA IgA, EBV EA IgA and EBV VCA IgA, and EBV EBNA and EBV VCA IgA is the same, 2.97 year. The PCDP of combining EBV BamHI-W and EBV VCA IgA is longest, 3.01 year. The estimated value is close to the true value in the model of mixture type tumor by simulation method. The sensitivity of simulation model is also close to that of meta-analysis. In cost-effectiveness analysis, the ICER (incremental cost-effectiveness ratio) is 365,095 when the strategy of no screening and 2-year screening with EBV VCA IgA is compared. The ICER is 442,145 with no screening and annually screening with EBV VCA IgA. The ICER is 1,091,533 with no screening and annually screening with combining EBV VCA IgA and nasopharyngoscope. Compared with no screening, 2-year screening with EBV VCA IgA can reduce one NPC death per 17,857 screening, annual screening with EBV VCA IgA can reduce one NPC death per 23,622 screening, and annual screening with combining EBV VCA IgA and nasopharyngoscope can reduce one NPC death per 21,739. The novelty of this study is combining the idea of sensitivity and multi-state model. In this way, the sensitivity of detection modalities has taken the influence of time progression into account. This method can be applied in disease screening in terms of screening interval determination and cost-effectiveness analysis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:36:56Z (GMT). No. of bitstreams: 1 ntu-96-P94846003-1.pdf: 897624 bytes, checksum: 0c26016385e5f60ea6bb79c05f99798d (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 中文摘要………………………………………………………………………………i
英文摘要………………………………………………………………………..…..…iv 第一章 背景………………………………………………………………………..1-1 第二章 文獻回顧…………………………………………………………………..2-1 第1節 鼻咽癌和EBV (Ebstein-Barr virus)的關係…….…………..….……2-1 第2節 單一鼻咽癌的篩檢工具……………………………………….….…2-2 第3節 合併多重鼻咽癌篩檢工具………………………………………..…2-6 第4節 篩檢工具敏感度及精確度之發展………………………………..…2-7 第5節 多階段模式和檢測工具敏感度的關連……………………………..2-8 第三章 材料和方法…………………………………………………………..……3-1 第1節 單一檢測工具敏感度和精確度的整合分析………………….….…3-2 第2節 合併多重檢測工具後的敏感度和精確度的方法………………..…3-7 第3節 疾病多階段模式和敏感度(sensitivity)的關連…………………..….3-8 第4節 多重檢測工具篩檢鼻咽癌的經濟效益分析………………………3-14 第四章 結果………………………………………………..………………………4-1 第1節 單一檢測工具的敏感度和精確度的整合分析………………….…..4-1 第2節 貝氏條件相依模式下合併多重工具的敏感度和精確度………......4-2 第3節 疾病多階段模式和敏感度的關連……………………………..……4-3 第4節 模擬四階段疾病自然史參數的結果………..……………….……....4-4 第5節 合併兩種檢測工具檢測兩類型腫瘤的成本效益分析結果……...…4-7 第五章 討論……………………………………………………………………...5-1 第六章 結論……………………………………………………………….…..…6-1 參考文獻………………………………………………………………………...……7-1 Multiple detection modalities for nasopharyngeal carcinoma—a meta-analysis of systemic review………………………………………………………………………8-1 Stochastic model for multiple detection modalities for early detection of screen-detectable disease ……………………………………………………………9-1 | |
dc.language.iso | zh-TW | |
dc.title | 鼻咽癌多重篩檢工具的評估 | zh_TW |
dc.title | Evaluation of Multiple Detection Modalities for Nasopharyngeal Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 嚴明芳 | |
dc.contributor.oralexamcommittee | 許志宏,張淑惠,戴政 | |
dc.subject.keyword | 篩檢,鼻咽癌,敏感度,精確度, | zh_TW |
dc.subject.keyword | Detection modalities,Nasopharyngeal carcinoma,Sensitivity,Specificity, | en |
dc.relation.page | 154 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-26 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 876.59 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。